Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The core mechanism of Late-onset
hypogonadism
(LOH) is the deficiency of androgen due to the functional and quantitative decline of testicular Leydig cells. Here we explored the protective effect of calretinin, a Ca
2+
-binding protein, on Leydig cells. We found in MLTC-1 cells transfected with LV-calb2, the cell viability and optical density (OD) were higher (
p
<0.05), cells in the S phase of the cell cycle were increased (
p
<0.01) and p-ERK1/2 and p-AKT levels were significantly higher (
p
<0.01 and
p
<0.05), while in R2C cells transfected with LV-siRNA-calb2, all of the results mentioned above were adverse (
p
<0.05). The cell apoptotic index after calretinin over-expressed was significantly lower (
p
<0.001), while the expression levels of mitochondria-related apoptotic factors such as cleaved
caspase-9
and cytochrome C (cyto C) were lower and ratio of Bcl2/Bax was higher (
p<
0.05). After calretinin down-regulated, the apoptotic index was higher (
p<
0.05), while the expression levels of mitochondria-related apoptotic factors were higher and the ratio of Bcl2/Bax was lower (
p<
0.05). Therefore, calretinin increases Leydig cell viability and proliferation, possibly via ERK1/2 and AKT pathways, and suppresses apoptosis possibly via the mitochondria-related apoptotic pathway, which could be beneficial in understanding the pathophysiology of LOH and could lead to the study of new treatments.
...
PMID:Protective effect of calretinin on testicular Leydig cells via the inhibition of apoptosis. 2843 48
